| Literature DB >> 28225011 |
Yizhe Chen1, Jing Zhou1, Gang Li1, Zhihui Tong1, Jie Dong1, Yiyuan Pan1, Lu Ke1, Weiqin Li1, Jieshou Li1.
Abstract
Abdominal bleeding is a lethal complication in acute pancreatitis (AP) and it is commonly described as a late event. However, spontaneous intra-abdominal bleeding could occur very early but no study focusing on this phenomenon was published yet. In this study, 1137 AP patients were retrospectively screened and 24 subjects suffering early spontaneous bleeding (ESB) were selected. Meanwhile, a 1:1 well-balanced cohort of non-bleeding patients was generated by propensity score match. The clinical characteristics of these patients were compared and a multiple regression analysis was performed to assess the risk factors for ESB. Besides, patients with massive post-intervention bleeding (PIB) were collected for additional comparison. ESB patients suffered significantly worse outcome than the matched cohort evidenced by dramatically higher mortality than the non-bleeding patients and even the PIB group (54.2% versus 20.8%, P = 0.017; 54.2% versus 31.0%, P = 0.049). The regression analysis demonstrated computer tomography severity index (CTSI; OR, 3.34; 95% CI, 1.995-5.59, P < 0.001) and creatinine (OR, 1.008; 95% CI, 1.004-1.012, P < 0.001) were associated with the occurrence of ESB. In conclusion, ESB is a rare but dangerous complication of moderate-to-severe AP and may result in high mortality. CTSI and creatinine are independent risk factors for the development of ESB.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28225011 PMCID: PMC5320508 DOI: 10.1038/srep42607
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study flowchart.
Baseline characteristics of ESB, Non-bleeding, and PIB Patients.
| Variable | ESB Group (n = 24) | Non-bleeding Group (n = 24) | PIB Group (n = 58) | ||
|---|---|---|---|---|---|
| Age, years | 43 (36–47.25) | 45.5 (34.75–49.5) | NS (0.570) | 46 (39–51) | NS (0.155) |
| Gender, M/F | 19/5 | 17/7 | NS (0.505) | 48/10 | NS (0.702) |
| BMI, kg/m2 | 24.8 (22.2–28.5) | 25.5 (21.17–27.75) | NS (0.836) | 25.25 (23.08–27.59) | NS (0.967) |
| Onset to admission, days | 18.5 (5.75–26.5) | 10 (6–41.25) | NS (0.844) | 23 (9.5–40) | NS (0.089) |
| Etiology, no. (%) | NS (0.499) | NS (0.99) | |||
| Biliary | 13 (54.2) | 16 (66.7) | 32 (55.2) | ||
| HTG | 9 (37.5) | 8 (33.3) | 20 (34.5) | ||
| Alcoholic | 1 (4.2) | 0 (0) | 3 (5.2) | ||
| Other | 1 (4.2) | 0 (0) | 3 (5.2) | ||
| Co-morbidities, no. (%) | |||||
| Smoking | 10 (41.7) | 8 (33.3) | NS (0.551) | 29 (50.0) | NS (0.492) |
| Alcohol use | 12 (50) | 9 (37.5) | NS (0.383) | 24 (41.4) | NS (0.474) |
| Hypertension | 7 (29.2) | 11 (45.8) | NS (0.233) | 19 (32.8) | NS (0.750) |
| Diabetes mellitus | 5 (20.8) | 7 (29.2) | NS (0.505) | 9 (15.5) | NS (0.560) |
| Coronary heart disease | 0 (0) | 2 (8.3) | NS (0.149) | 4 (6.9) | NS (0.187) |
| Fatty liver | 3 (12.5) | 5 (20.8) | NS (0.439) | 12 (20.7) | NS (0.383) |
| Chronic respiratory disease | 2 (8.3) | 3 (12.5) | NS (0.637) | 8 (13.8) | NS (0.492) |
| Chronic renal disease | 0 (0) | 1 (4.2) | NS (0.312) | 1 (1.7) | NS (0.517) |
BMI body mass index, HTG hypertriglyceridemia. *ESB Group versus Non-bleeding Group, †ESB Group versus PIB Group. Data are expressed as median (interquartile range) for continuous variables and frequencies (proportions) for categorical variables, as appropriate. Mann–Whitney U-test and Pearson test was used as the circumstances required.
Comparison of ESB patients and Non-bleeding patients on admission.
| Variable | ESB Group (n = 24) | Non-bleeding Group (n = 24) | |
|---|---|---|---|
| Temperature, °C | 37.85 (36.53–38.58) | 37.5 (37.08–38.2) | NS (0.702) |
| MAP, mmHg | 94.33 (73.33–108.67) | 93.33 (87.92–103.83) | NS (0.885) |
| Heart rate | 113.5 (100.5–131.5) | 114 (91.25–127.75) | NS (0.680) |
| Respiratory rate | 26 (22.25–34.25) | 24 (18.25–34.5) | NS (0.337) |
| IAP, mmHg | 11.7 (8.7–14.65) | 9.15 (7.45–12.0) | NS (0.066) |
| Hemoglobin, g/L | 81.5 (73.25–99) | 91.5 (78–99.0) | NS (0.312) |
| Platelet count, x109 cells/L | 188 (135.75–299.5) | 203 (121.75–278) | NS (0.975) |
| PT, s | 13.65 (12.8–14.75) | 14.45 (13.03–16.6) | NS (0.208) |
| APTT, s | 36.6 (31.83–42.33) | 36.75 (28.6–43.53) | NS (0.902) |
| INR | 1.2 (1.11–1.4) | 1.23 (1.16–1.29) | NS (0.628) |
| C-reactive protein, mg/L | 125.9 (89.9–182.1) | 117.7 (80.8–183.15) | NS (0.585) |
| Total bilirubin, umol/L | 26.3 (15.6–83.0) | 21.8 (10.78–52.98) | NS (0.364) |
| Unconjugated bilirubin, umol/L | 10.9 (5.0–34.5) | 7.0 (2.93–13.9) | NS (0.197) |
| ALT, U/L | 24.5 (12.25–48.25) | 32.5 (25.25–60.5) | NS (0.173) |
| AST, U/L | 29 (22.5–88.5) | 37 (25.25–67) | NS (0.585) |
| BUN, mmol/L | 10.7 (4.8–20.6) | 5.6 (2.8–9.5) | 0.008 |
| Creatinine, umol/L | 207.5 (58.8–339.5) | 58 (38–114) | 0.007 |
| CTSI | 10 (10–10) | 8 (6–10) | 0.005 |
| APACHE II score | 15.5 (9–22.3) | 15.5 (10.25–22.75) | NS (0.885) |
| SOFA score | 6 (2.25–8.75) | 3 (2–6) | NS (0.076) |
MAP mean arterial pressure, IAP intra-abdominal pressure, PT prothrombin time, APTT activated partial thromboplastin time, INR international normalized ratio, ALT alanine transaminase, AST aspartate transaminase, BUN blood urea nitrogen, CTSI computer tomography severity index, APACHE acute physiology and chronic health evaluation, SOFA sequential organ failure assessment. Data are expressed as median (interquartile range) for continuous variables and frequencies (proportions) for categorical variables, as appropriate. Mann–Whitney U-test and Pearson test was used as the circumstances required.
Clinical course and outcome between ESB patients and Non-bleeding patients.
| Variable | ESB Group (n = 24) | Non-bleeding Group (n = 24) | |
|---|---|---|---|
| IPN, no. (%) | 19 (79.2) | 15 (62.5) | NS (0.204) |
| Digestive tract fistula, no. (%) | 10 (41.7) | 6 (25.0) | NS (0.221) |
| SVT, no. (%) | 5 (20.8) | 5 (20.8) | NS (1) |
| ACS, no. (%) | 7 (29.2) | 0 (0) | 0.004 |
| Organ failure | |||
| Shock, no. (%) | 16 (66.7) | 8 (33.3) | 0.021 |
| ARDS, no. (%) | 19 (79.2) | 15 (62.5) | NS (0.204) |
| AKI, no. (%) | 17 (70.8) | 10 (41.6) | 0.042 |
| ALI, no. (%) | 13 (54.2) | 6 (25.0) | 0.039 |
| MODS, no. (%) | 18 (75.0) | 8 (33.3) | 0.004 |
| Management | |||
| CRRT, no. (%) | 16 (66.7) | 8 (33.3) | 0.021 |
| PCD, no. (%) | 20 (83.3) | 13 (54.2) | 0.029 |
| NPI, no. (%) | 18 (75.0) | 8 (33.3) | 0.004 |
| ED, no. (%) | 11 (45.8) | 8 (33.3) | NS (0.376) |
| DSA, no. (%) | 17 (70.8) | 5 (20.8) | 0.001 |
| Laparotomy, no. (%) | 12 (50.0) | 6 (25.0) | NS (0.074) |
| Revised Atlanta classification | 0.001 | ||
| Mild, no. (%) | 0 (0) | 0 (0) | |
| Moderate severe, no. (%) | 2 (8.3) | 13 (54.2) | |
| Severe, no. (%) | 22 (91.7) | 11 (45.8) | |
| Mortality, no. (%) | 13 (54.2) | 5 (20.8) | 0.017 |
| Hospital duration, days | 35 (19.5–83.75) | 13.5 (8–64.5) | NS (0.060) |
| ICU duration, days | 24.5 (12.75–46.25) | 9 (4.25–33.75) | 0.042 |
| Cost, thousand CNY | 293 (183–459) | 120 (49–449) | 0.026 |
IPN infected pancreatic necrosis, SVT splanchnic venous thrombosis, ACS abdominal compartment syndrome, ARDS acute respiratory distress syndrome, AKI acute kidney injury, ALI acute liver injury, MODS multiple organ dysfunction syndrome, CRRT continuous renal replacement therapy, PCD percutaneous catheter drainage, NPI negative pressure irrigation, ED endoscopic necrosectomy, DSA digital subtraction angiography, ICU intensive care unit. Data are expressed as median (interquartile range) for continuous variables and frequencies (proportions) for categorical variables, as appropriate. Mann–Whitney U-test and Pearson test was used as the circumstances required.
Univariate logistic regression analysis of ESB.
| Variable | Odds Ratio | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Age | 0.955 | 0.896 | 1.018 | 0.155 |
| Gender | 1.105 | 0.141 | 8.679 | 0.925 |
| Etiology | 1.136 | 0.399 | 3.234 | 0.812 |
| Smoking | 0.978 | 0.162 | 5.909 | 0.981 |
| Alcohol use | 0.169 | 0.023 | 1.236 | 0.080 |
| Platelet count | 1.002 | 0.995 | 1.009 | 0.611 |
| PT | 0.444 | 0.216 | 0.913 | 0.027 |
| APTT | 0.997 | 0.954 | 1.042 | 0.889 |
| INR | 1497.253 | 0.385 | 5822920.583 | 0.083 |
| C-reactive protein | 0.991 | 0.979 | 1.004 | 0.173 |
| Total bilirubin | 0.996 | 0.982 | 1.010 | 0.585 |
| Unconjugated bilirubin | 1.050 | 0.982 | 1.123 | 0.152 |
| BUN | 0.962 | 0.772 | 1.198 | 0.730 |
| Creatinine | 1.018 | 1.004 | 1.032 | 0.011 |
| CTSI | 5.764 | 2.378 | 13.971 | <0.001 |
| APACHE II score | 0.906 | 0.793 | 1.036 | 0.148 |
PT prothrombin time, APTT activated partial thromboplastin time, INR international normalized ratio, BUN blood urea nitrogen, CTSI computer tomography severity index, APACHE acute physiology and chronic health evaluation.
Independent prognostic factors in a multivariate logistic regression analysis of ESB.
| Variable | Odds Ratio | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| CTSI | 3.340 | 1.995 | 5.590 | <0.001 |
| Creatinine | 1.008 | 1.004 | 1.012 | <0.001 |
CTSI computer tomography severity index.
Admission status, clinical course and outcome between ESB patients and PIB patients.
| Variable | ESB Group (n = 24) | PIB Group (n = 58) | |
|---|---|---|---|
| Hemoglobin, g/L | 81.5 (73.25–99) | 91 (79.75–101.5) | NS (0.142) |
| Platelet count, ×109 cells/L | 188 (135.75–299.5) | 186 (106.75–284) | NS (0.795) |
| PT, s | 13.65 (12.8–14.75) | 13.45 (12.15–14.8) | NS (0.71) |
| APTT, s | 36.6 (31.83–42.33) | 33.5 (27.95–40.35) | NS (0.154) |
| INR | 1.2 (1.11–1.4) | 1.17 (1.055–1.2725) | NS (0.177) |
| C-reactive protein, mg/L | 125.9 (89.9–182.1) | 131.45 (96.675–191) | NS (0.744) |
| Total bilirubin, umol/L | 26.3 (15.6–83) | 24.15 (13.5–55.25) | NS (0.488) |
| Unconjugated bilirubin, umol/L | 10.9 (5.0–34.5) | 6.55 (3.55–13.075) | NS (0.06) |
| ALT, U/L | 24.5 (12.25–48.25) | 32 (21–56) | NS (0.243) |
| AST, U/L | 29 (22.5–88.5) | 34.5 (24–54.25) | NS (0.919) |
| BUN, mmol/L | 10.7 (4.8–20.6) | 9.1 (5.35–14.725) | NS (0.415) |
| Creatinine, umol/L | 207.5 (58.8–339.5) | 81.5 (49.5–188.5) | 0.037 |
| APACHE II score | 15.5 (9–22.3) | 11.5 (8.75–15) | 0.032 |
| Onset to bleeding, days | 17.5 (10–20) | 51 (26.75–70.75) | <0.001 |
| IPN, no. (%) | 19 (79.2) | 56 (96.6) | 0.010 |
| Digestive tract fistula, no. (%) | 10 (41.7) | 28 (48.3) | NS (0.585) |
| SVT, no. (%) | 5 (20.8) | 13 (22.4) | NS (0.875) |
| ACS, no. (%) | 7 (29.2) | 10 (17.2) | NS (0.225) |
| Organ failure | |||
| Shock, no. (%) | 16 (66.7) | 37 (63.8) | NS (0.804) |
| ARDS, no. (%) | 19 (79.2) | 39 (67.2) | NS (0.280) |
| AKI, no. (%) | 17 (70.8) | 34 (58.6) | NS (0.299) |
| ALI, no. (%) | 13 (54.2) | 15 (25.9) | 0.014 |
| MODS, no. (%) | 18 (75.0) | 37 (63.8) | NS (0.326) |
| Revised Atlanta classification | NS (0.230) | ||
| Mild, no. (%) | 0 (0) | 0 (0) | |
| Moderate severe, no. (%) | 2 (8.3) | 11 (19.0) | |
| Severe, no. (%) | 22 (91.7) | 47 (81.0) | |
| Mortality, no. (%) | 13 (54.2) | 18 (31.0) | 0.049 |
| Hospital duration, days | 35 (19.5–83.75) | 52 (27–78) | NS (0.343) |
| ICU duration, days | 24.5 (12.75–46.25) | 35 (18.25–53.25) | NS (0.375) |
| Cost, thousand CNY | 293 (183–459) | 416 (256–553) | NS (0.433) |
PT prothrombin time, APTT activated partial thromboplastin time, INR international normalized ratio, ALT alanine transaminase, AST aspartate transaminase, BUN blood urea nitrogen, APACHE acute physiology and chronic health evaluation, IPN infected pancreatic necrosis, SVT splanchnic venous thrombosis, ACS abdominal compartment syndrome, ARDS acute respiratory distress syndrome, AKI acute kidney injury, ALI acute liver injury, MODS multiple organ dysfunction syndrome, ICU intensive care unit. Data are expressed as median (interquartile range) for continuous variables and frequencies (proportions) for categorical variables, as appropriate. Mann–Whitney U-test and Pearson test was used as the circumstances required.
Figure 2Distribution of survival time between ESB group and PIB group (Mann–Whitney U-test).
The lines in the figure refer to the median survival time of patients (ESB group: 46[30.5–72] days vs PIB group: 73.5[57.75–112.75] days, P = 0.010).